Announcements Trials
Browse Landscape

Phase

Phase 2 41Phase 3 7Phase 1/2 6Phase NA 3Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasms 314Carcinoma, Non-Small-Cell Lung 162Breast Neoplasms 125Neoplasm Metastasis 106Melanoma 95Leukemia, Myeloid, Acute 80Lymphoma 79Multiple Myeloma 74Colorectal Neoplasms 73Ovarian Neoplasms 70Lymphoma, Non-Hodgkin 63Recurrence 58Prostatic Neoplasms 56Pancreatic Neoplasms 51Lung Neoplasms 50Carcinoma, Renal Cell 40Glioblastoma 39Precursor Cell Lymphoblastic Leukemia-Lymphoma 38Lymphoma, Large B-Cell, Diffuse 37Leukemia, Lymphocytic, Chronic, B-Cell 37Advanced Solid Tumors 37Leukemia 36Myelodysplastic Syndromes 35Triple Negative Breast Neoplasms 34Head and Neck Neoplasms 33Sarcoma 31Brain Neoplasms 31Urinary Bladder Neoplasms 30Stomach Neoplasms 30Lymphoma, Follicular 28

Interventions

Metformin 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Has results × Leukemia, Myelomonocytic, Acute × Clear all
NCT01849276 2019-01-31

Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML

Northwestern University

Phase 1 Terminated
2 enrolled 9 charts
Other hematologic neoplasm

Congenital Abnormalities, Blast Crisis, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡